RT Journal Article
SR Electronic
T1 Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP e001153
DO 10.1136/lupus-2024-001153
VO 11
IS 1
A1 Moreno-Torres, Víctor
A1 Martínez-Urbistondo, María
A1 Vázquez-Comendador, José
A1 Mateos Seirul-lo, María
A1 Castejón, Raquel
A1 Huerta, Ana
A1 Durán-del Campo, Pedro
A1 Tutor, Pablo
A1 Mellor-Pita, Susana
YR 2024
UL http://lupus.bmj.com/content/11/1/e001153.abstract
AB Objective To evaluate the impact of the different types of neoplasms and lineages on mortality of patients with SLE.Methods Retrospective and observational comparison of the neoplasm-related deaths in patients with SLE and the general Spanish population reported in the Spanish Hospital Discharge Database. To determine the impact of SLE on the risk of dying from each neoplasm lineage, a binary logistic regression considering age, female sex, tobacco and alcohol consumption, was performed.Results During 2016–2019, 139 531 in-hospital deaths from neoplasms were certified in Spain (91 in patients with SLE). Patients with SLE presented a lower mortality rate from solid organ neoplasms, (80.2% vs 91.1%, OR 0.393), linked to their lower risk of colorectal carcinoma (1.1% vs 10.8%, OR 0.110). By contrast, gynaecological neoplasms presented a higher risk (8.8% vs 3%, OR 3.039) in the deceased patients with SLE, associated with the higher frequency of vulvar neoplasms (2% vs 0.2%, OR 14.767) and cervical carcinomas (3.3% vs 0.5%, OR 3.809). Haematological neoplasm-related deaths were also more prevalent in patients with SLE (19.8% vs 8.9%, OR 2.546), mostly attributable to the higher proportion of deaths due to non-Hodgkin’s lymphoma (11% vs 2.9%, OR 4.060) of B cell lineage (9.9% vs 2.5%, OR 4.133).Conclusions Patients with SLE present a higher risk of death from vulvar neoplasms, cervical carcinomas and B-cell non-Hodgkin’s lymphoma in comparison with the general Spanish population. In addition to developing strategies that might help to attenuate their occurrence and impact, such as decreasing the immunosuppressive burden, specific early detection programmes for these conditions should be investigated and considered carefully.Data are available in a public, open access repository. The data analysed are extracted from the Spanish Hospital Discharge Database (SNHDD)—a public access registry belonging to the Spanish Government.